Bolt Biotherapeutics Inc.
Organization details
- Legal name
- Bolt Biotherapeutics Inc.
- Former names
- Bolt Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Redwood City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BOLT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001641281
- EIN
- 47-2804636
Board of directors
-
Brian O'callaghan · DirectorSince 2023
-
Edgar Engleman · DirectorSince 2023
-
Frank D. Lee · DirectorSince 2023
-
Jakob Dupont · DirectorSince 2024
- Since 2023
-
Kathleen Laporte · DirectorSince 2023
-
Laura Berner · DirectorSince 2023
-
Mahendra Shah · DirectorSince 2023
-
Nicole Onetto · DirectorSince 2023
-
Randall C. Schatzman · Director · Chief Executive OfficerSince 2023
-
Richard A. Miller M.D. · DirectorSince 2023
-
Sheila Gujrathi · Director · Chief Strategy OfficerSince 2026
-
William P. Quinn · Director · President, CEO and CFOSince 2024
Chief executives
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
87.0%
-
93.9%
Board connections
6 of this board's directors also sit on 14 other boards. 13 are in the same sector.
-
ArriVent BioPharma Inc. Same sectorvia James Healy
-
Bausch Health Companies Inc. Same sectorvia Frank D. Lee
-
BioAge Labs Inc. Same sectorvia James Healy
-
BlossomHill Therapeutics Inc. Same sectorvia Sheila Gujrathi
-
Corvus Pharmaceuticals Inc. Same sectorvia Richard A. Miller M.D.
-
Janux Therapeutics Inc. Same sectorvia Sheila Gujrathi
-
Natera Inc. Same sectorvia James Healy
-
Pacira BioSciences Inc. Same sectorvia Frank D. Lee
- via Kathleen Laporte
-
Processa Pharmaceuticals Inc. Same sectorvia Sheila Gujrathi
-
Pyxis Oncology Inc. Same sectorvia Jakob Dupont
-
Q32 Bio Inc. Same sectorvia Kathleen Laporte
-
Rapport Therapeutics Inc. Same sectorvia James Healy
-
Seaport Therapeutics Inc. Same sectorvia James Healy
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $324,599
- 5 purchases by 3 insiders
- Sold, last 12 months
- $128,361
- 9 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 9, 2026 | Coastlands Capital LP 10% owner | Open-market purchase | +50,000 | $6.38 | $319,000 |
| Oct 23, 2026 | Sheila Gujrathi Director, Officer (Chief Strategy Officer) | Grant or award | +72,766 | — | — |
| Oct 23, 2026 | Sheila Gujrathi Director, Officer (Chief Strategy Officer) | Grant or award | +13,055 | — | — |
| Sep 18, 2026 | Yonehiro Grant Officer (Chief Operating Officer) | Open-market sale | −6,850 | $3.24 | $22,194 |
| Sep 18, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market sale | −9,132 | $3.24 | $29,588 |
| Sep 18, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market sale | −4,077 | $3.24 | $13,209 |
| Sep 17, 2026 | Yonehiro Grant Officer (Chief Operating Officer) | Open-market sale | −4,909 | $3.32 | $16,298 |
| Sep 17, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market sale | −6,545 | $3.32 | $21,729 |
| Sep 17, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market sale | −2,922 | $3.32 | $9,701 |
| Sep 16, 2026 | Yonehiro Grant Officer (Chief Operating Officer) | Open-market sale | −1,417 | $3.77 | $5,342 |
| Sep 16, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market sale | −1,889 | $3.77 | $7,122 |
| Sep 16, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market sale | −843 | $3.77 | $3,178 |
| Jun 5, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market purchase | +637 | $3.88 | $2,472 |
| Jun 5, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market purchase | +509 | $3.88 | $1,975 |
| Dec 5, 2025 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market purchase | +125 | $4.61 | $576 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Bolt Biotherapeutics Inc.
Who is the CEO of Bolt Biotherapeutics Inc.?
Randall C. Schatzman is Bolt Biotherapeutics Inc.'s Chief Executive Officer.
How many directors are on Bolt Biotherapeutics Inc.'s board?
Bolt Biotherapeutics Inc.'s board has 13 directors: Brian O'callaghan, Edgar Engleman, Frank D. Lee, Jakob Dupont, James Healy, Kathleen Laporte, Laura Berner, Mahendra Shah, Nicole Onetto, Randall C. Schatzman and 3 others.
Are Bolt Biotherapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Bolt Biotherapeutics Inc. insiders bought $324,599 of shares in 5 purchases and sold $128,361 of shares in 9 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="bolt-biotherapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.